The "Fore The Fight: One Tough Titty Charity Golf Outing" is June 20 at Boulder Creek Golf Club. Foursomes can still sign up ...

Researchers at the University of Glasgow have received £399,670 in funding from Breast Cancer Now and Secondary1st to develop ...

Researchers from the Hong Kong University of Science and Technology (HKUST) have developed Mixture of Modality Experts (MOME) ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...

Adding another member to your family is supposed to be one of the happiest times of your life, but for one woman, it turned ...

BY DR. AMANI JAMBHEKARCHRISTUS St. Vincent Specialists ClinicLos Alamos My name is Amani Jambhekar and I’m a breast cancer and melanoma surgeon in Santa Fe, NM. I’m also certified in Cancer ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.